In Reply
- PMID: 29510828
- PMCID: PMC5842350
- DOI: 10.3238/arztebl.2018.0115
In Reply
Comment on
-
Central Problem is Equipoise.Dtsch Arztebl Int. 2018 Feb 16;115(7):114. doi: 10.3238/arztebl.2018.0114a. Dtsch Arztebl Int. 2018. PMID: 29510825 Free PMC article. No abstract available.
-
No Substitute for a Doctor's Intuition.Dtsch Arztebl Int. 2018 Feb 16;115(7):114. doi: 10.3238/arztebl.2018.0114b. Dtsch Arztebl Int. 2018. PMID: 29510826 Free PMC article. No abstract available.
-
Real-World Usefulness Is Missing.Dtsch Arztebl Int. 2018 Feb 16;115(7):114-115. doi: 10.3238/arztebl.2018.0114c. Dtsch Arztebl Int. 2018. PMID: 29510827 Free PMC article. No abstract available.
-
A Rare Cause of Splenomegaly.Dtsch Arztebl Int. 2018 Feb 16;115(7):116. doi: 10.3238/arztebl.2018.0116b. Dtsch Arztebl Int. 2018. PMID: 29510830 Free PMC article. No abstract available.
References
-
- Delaloge S, Pérol D, Courtinard C, et al. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Ann Oncol. 2016;27:1725–1732. - PubMed
-
- Macleod MR, Michie S, Roberts I, et al. Biomedical research: increasing value, reducing waste. Lancet. 2014;383:101–104. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
